Experimental Study of Intralymphatic Chemotherapy in Rabbits.

为了检验淋巴内化疗的临床有效性和适当的抗癌药物方案，我们测量了VX2癌兔及其对照组淋巴内给药futrul （FT）或neocarzinostatatin （NCS）后的血清和组织药物水平。实验结果如下：1)将FT等低分子药物注入淋巴管后，大部分药物经胸导管进入体循环，部分药物从淋巴管渗漏，经肠进入门静脉。2)对于NCS等高分子量药物，其有留在淋巴结的倾向。因此，高分子量的药物似乎最适合用于淋巴内给药。4)转移性淋巴结中，淋巴内注射组NCS浓度高于静脉注射组。5)淋巴内给药似乎不依赖于转移程度。

In order to examine the clinical usefulness of intralymphatic chemotherapy and the regimen of the appropriate anticancer drug for this route, we measured serum and tissue drug levels following intralymphatic administration of futraful (FT) or neocarzinostatin (NCS) in rabbits with VX2 carcinoma and their control.The results were as follows; 1) when a low - molecular - weight drug such as FT was administered into the lymphatic vessels, most of the drug flowed into the systemic circulation through the thoracic duct, but some leaked from the lymphatic vessels and flowed into the portal vein via the intestine. 2) In the case of high - molecular - weight drug such as NCS, there was a tendency for it to remain in the lymph nodes. 3) It i therefore seems that a drug of high - molecular - weight is most suitable for use in intralymphatic administration. 4) In metastatic lymphnode, tissue level of NCS in intralymphatic group showed high concentration than in intravenous group. 5) It seems that intralymphatic administration do not depend upon the degree of metastase.